MODIFIZIERTE L-ASPARAGINASE

European patent · EP3642340 · In force

Register entry

Publication number
EP3642340
Application number
EP18731853
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 21, 2018
Published
Apr 29, 2020
Granted
Mar 20, 2024
Protection ends at the latest
Jun 20, 2038
Next annual fee due
Jun 30, 2027
IPC classes
C12N 9/82 (2006.01)
Priority
EP 17177237 21.06.2017
US 201762523061 P 21.06.2017
US 201715671086 07.08.2017
PCT application
PCT/EP2018/066647 21.06.2018
PCT publication
WO2018/234492 27.12.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jan 29, 2025

    Change

    Published in Swissreg on 29.01.2025

  4. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  5. May 30, 2024

    Agent entered

    Representative
    E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich

    Published in Swissreg on 30.05.2024

  6. Mar 20, 2024

    Granted

    Published in Swissreg on 20.03.2024

Parties

Holder

Jazz Pharmaceuticals Ireland Limited

Fifth Floor, Waterloo Exchange Waterloo Road, 4 Dublin, IE

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

FRIEDRICH, Lars

60638 Munich, DE

O'DONNELL, Anne

10 Dublin, IE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.